Joan Massagu Sol

List of Publications by Year in Descending Order

249 papers	103,197 citations	141 h-index	269 g-index
269 ext. papers	112,376 ext. citations	25 avg, IF	8.79 L-index

#	Paper	IF	Citations
249	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. *Cell*, **2022**, 185, 563-575.e11	56.2	11
248	Metastasis-Initiating Cells and Ecosystems. *Cancer Discovery*, **2021**, 11, 971-994	24.4	22
247	The transcription factor Rreb1 regulates epithelial architecture, invasiveness, and vasculogenesis in early mouse embryos. *ELife*, **2021**, 10,	8.9	1
246	Anti-tumor effects of an ID antagonist with no observed acquired resistance. *Npj Breast Cancer*, **2021**, 7, 58	7.8	0
245	Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. *Immunity*, **2021**, 54, 1037-1054.e7	32.3	15
244	Targeting metastatic cancer. *Nature Medicine*, **2021**, 27, 34-44	50.5	102
243	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. *Cancer Research*, **2020**, 80, 4314-4323	10.1	25
242	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. *Nature Medicine*, **2020**, 26, 259-269	50.5	127
241	Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. *Molecular Cancer Research*, **2020**, 18, 599-611	6.6	27
240	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. *Nature Cancer*, **2020**, 1, 28-45	15.4	59
239	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell*, **2020**, 181, 236-249	56.2	140
238	TGF-□orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. *Nature*, **2020**, 577, 566-571	50.4	109
237	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. *Neuro-Oncology Advances*, **2020**, 2, ii10-ii11	0.9	78
236	ID1 Mediates Escape from TGF□Tumor Suppression in Pancreatic Cancer. *Cancer Discovery*, **2020**, 10, 142-157	24.4	26
235	Guidelines and definitions for research on epithelial-mesenchymal transition. *Nature Reviews Molecular Cell Biology*, **2020**, 21, 341-352	48.7	469
234	Structural basis for distinct roles of SMAD2 and SMAD3 in FOXH1 pioneer-directed TGF-□signaling. *Genes and Development*, **2019**, 33, 1506-1524	12.6	28
233	H3K18ac Primes Mesendodermal Differentiation upon Nodal Signaling. *Stem Cell Reports*, **2019**, 13, 642-656	8	4

232	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. *Cancer Cell*, **2019**, 36, 402-417.e13	24.3	37
231	A rectal cancer organoid platform to study individual responses to chemoradiation. *Nature Medicine* , **2019**, 25, 1607-1614	50.5	149
230	Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation. *Nature Genetics*, **2019**, 51, 999-1010	36.3	44
229	Transforming Growth Factor-Signaling in Immunity and Cancer. *Immunity*, **2019**, 50, 924-940	32.3	666
228	Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. *ELife* , **2019**, 8,	8.9	26
227	Author response: Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization **2019**,		2
226	Labeling and Isolation of Fluorouracil Tagged RNA by Cytosine Deaminase Expression. *Bio-protocol*, **2019**, 9, e3433	0.9	0
225	TGF-Inhibition and Immunotherapy: Checkmate. *Immunity*, **2018**, 48, 626-628	32.3	77
224	Contextual determinants of TGFaction in development, immunity and cancer. *Nature Reviews Molecular Cell Biology*, **2018**, 19, 419-435	48.7	335
223	Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. *Nature Cell Biology*, **2018**, 20, 966-978	23.4	98
222	Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. *Cell*, **2017**, 168, 1101-1113.e13	56.2	139
221	Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases. *Nanoscale*, **2017**, 9, 1110-1119	7.7	34
220	Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors. *Nature Communications*, **2017**, 8, 2070	17.4	46
219	The p53 Family Coordinates Wnt and Nodal Inputs in Mesendodermal Differentiation of Embryonic Stem Cells. *Cell Stem Cell*, **2017**, 20, 70-86	18	78
218	Metastatic colonization by circulating tumour cells. *Nature*, **2016**, 529, 298-306	50.4	1004
217	Arresting supporters: targeting neutrophils in metastasis. *Cell Research*, **2016**, 26, 273-4	24.7	13
216	Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. *Cell*, **2016**, 165, 45-60	56.2	399
215	Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. *Nature*, **2016**, 533, 493-498	50.4	426

214	TGF-β Tumor Suppression through a Lethal EMT. *Cell*, **2016**, 164, 1015-30	56.2	363
213	Therapy-induced tumour secretomes promote resistance and tumour progression. *Nature*, **2015**, 520, 368-72	50.4	317
212	Structural determinants of Smad function in TGF-β signaling. *Trends in Biochemical Sciences*, **2015**, 40, 296-308	10.3	219
211	Surviving at a Distance: Organ-Specific Metastasis. *Trends in Cancer*, **2015**, 1, 76-91	12.5	282
210	Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. *Cancer Research*, **2015**, 75, 3713-9	10.1	38
209	Invasion and Metastasis **2015**, 269-284.e2		4
208	Serpins promote cancer cell survival and vascular co-option in brain metastasis. *Cell*, **2014**, 156, 1002-16	56.2	491
207	Metastatic stem cells: sources, niches, and vital pathways. *Cell Stem Cell*, **2014**, 14, 306-21	18	472
206	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. *Nature Cell Biology*, **2014**, 16, 876-88	23.4	227
205	Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. *ELife*, **2014**, 3,	8.9	79
204	RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. *EMBO Molecular Medicine*, **2014**, 6, 865-81	12	51
203	Author response: Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer **2014**,		2
202	Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. *Cell*, **2013** , 154, 1060-1073	56.2	296
201	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. *Nature Medicine*, **2013**, 19, 50-6	50.5	148
200	Origins of metastatic traits. *Cancer Cell*, **2013**, 24, 410-21	24.3	367
199	TGF-β1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. *Cell Reports*, **2013**, 5, 1228-42	10.6	175
198	Signalling change: signal transduction through the decades. *Nature Reviews Molecular Cell Biology*, **2013**, 14, 393-8	48.7	43
197	Hypoxia signaling--license to metastasize. *Cancer Discovery*, **2013**, 3, 1103-4	24.4	6

196	Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. *Cancer Cell*, **2012**, 22, 571-84	24.3	690
195	Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. *Journal of Neuro-Oncology*, **2012**, 109, 229-38	4.8	14
194	TGF-β signalling in context. *Nature Reviews Molecular Cell Biology*, **2012**, 13, 616-30	48.7	2035
193	A CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell*, **2012**, 150, 165-78	56.2	720
192	Field cancerization: something new under the sun. *Cell*, **2012**, 149, 1179-81	56.2	33
191	Structural basis for the versatile interactions of Smad7 with regulator WW domains in TGF-β Pathways. *Structure*, **2012**, 20, 1726-36	5.2	82
190	Ubiquitin removal in the TGF-β pathway. *Nature Cell Biology*, **2012**, 14, 656-7	23.4	33
189	TGF-β control of stem cell differentiation genes. *FEBS Letters*, **2012**, 586, 1953-8	3.8	112
188	TGF-β signaling in development and disease. *FEBS Letters*, **2012**, 586, 1833	3.8	73
187	Extracellular matrix players in metastatic niches. *EMBO Journal*, **2012**, 31, 254-6	13	74
186	Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. *Clinical Cancer Research*, **2012**, 18, 5520-5	12.9	94
185	Clinical implications of cancer self-seeding. *Nature Reviews Clinical Oncology*, **2011**, 8, 369-77	19.4	213
184	Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. *Nature Medicine*, **2011**, 17, 867-74	50.5	636
183	A poised chromatin platform for TGF-β access to master regulators. *Cell*, **2011**, 147, 1511-24	56.2	209
182	Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. *Cancer Cell*, **2011**, 20, 538-49	24.3	399
181	VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. *Cancer Cell*, **2011**, 20, 701-14	24.3	363
180	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. *Clinical Breast Cancer*, **2011**, 11, 306-11	3	102
179	Breast cancer methylomes establish an epigenomic foundation for metastasis. *Science Translational Medicine*, **2011**, 3, 75ra25	17.5	215

178	Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. *Silence: A Journal of RNA Regulation*, **2011**, 2, 3		67
177	Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. *Journal of Clinical Oncology*, **2011**, 29, 2610-2	2.2	30
176	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. *Genes and Development*, **2011**, 25, 226-31	12.6	170
175	A Smad action turnover switch operated by WW domain readers of a phosphoserine code. *Genes and Development*, **2011**, 25, 1275-88	12.6	187
174	TIF1γ Knockdown Enhances Hematopoietic Stem Cell Self Renewal with Preferential Myeloid Differentiation and Delayed Erythropoiesis. *Blood*, **2011**, 118, 4829-4829	2.2	
173	HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPβ isoforms. *Cancer Research*, **2010**, 70, 9927-36	10.1	38
172	Modeling metastasis in the mouse. *Current Opinion in Pharmacology*, **2010**, 10, 571-7	5.1	95
171	Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis: in vivo and mechanistic studies on the migrastatin core ether analog. *Journal of the American Chemical Society*, **2010**, 132, 3224-8	16.4	61
170	ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. *Genes and Development*, **2009**, 23, 1882-94	12.6	235
169	Multimodality imaging of TGFbeta signaling in breast cancer metastases. *FASEB Journal*, **2009**, 23, 2662-72	6.9	43
168	Latent bone metastasis in breast cancer tied to Src-dependent survival signals. *Cancer Cell*, **2009**, 16, 67-78	24.3	534
167	Roles of TGFbeta in metastasis. *Cell Research*, **2009**, 19, 89-102	24.7	633
166	Genes that mediate breast cancer metastasis to the brain. *Nature*, **2009**, 459, 1005-9	50.4	1288
165	Metastasis: from dissemination to organ-specific colonization. *Nature Reviews Cancer*, **2009**, 9, 274-84	31.3	1934
164	WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. *Cell*, **2009**, 138, 51-62	56.2	443
163	Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. *Cell*, **2009**, 139, 757-69	56.2	550
162	Tumor self-seeding by circulating cancer cells. *Cell*, **2009**, 139, 1315-26	56.2	972
161	Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. *Molecular Cell*, **2009**, 36, 457-68	17.6	264

160	Endogenous human microRNAs that suppress breast cancer metastasis. *Nature*, **2008**, 451, 147-52	50.4	1571
159	A very private TGF-beta receptor embrace. *Molecular Cell*, **2008**, 29, 149-50	17.6	61
158	TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. *Cell*, **2008**, 133, 66-77	56.2	728
157	TGFbeta in Cancer. *Cell*, **2008**, 134, 215-30	56.2	2821
156	Molecular basis of metastasis. *New England Journal of Medicine*, **2008**, 359, 2814-23	59.2	791
155	Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program. *Journal of Biological Chemistry*, **2008**, 283, 1146-55	5.4	82
154	Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. *Nature Chemical Biology*, **2007**, 3, 498-507	11.7	140
153	Genetic determinants of cancer metastasis. *Nature Reviews Genetics*, **2007**, 8, 341-52	30.1	624
152	Beyond tumorigenesis: cancer stem cells in metastasis. *Cell Research*, **2007**, 17, 3-14	24.7	478
151	Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. *Nature*, **2007**, 446, 765-70	50.4	560
150	ID genes mediate tumor reinitiation during breast cancer lung metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 19506-11	11.5	210
149	Lung metastasis genes couple breast tumor size and metastatic spread. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 6740-5	11.5	305
148	Sorting out breast-cancer gene signatures. *New England Journal of Medicine*, **2007**, 356, 294-7	59.2	111
147	Balancing BMP signaling through integrated inputs into the Smad1 linker. *Molecular Cell*, **2007**, 25, 441-54	17.6	333
146	C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. *Cancer Cell*, **2006**, 10, 203-14	24.3	220
145	Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. *Journal of Biological Chemistry*, **2006**, 281, 40412-9	5.4	133
144	A FoxO-Smad synexpression group in human keratinocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 12747-52	11.5	188
143	Unique players in the BMP pathway: small C-terminal domain phosphatases dephosphorylate Smad1 to attenuate BMP signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 11940-5	11.5	108

142	The logic of TGFbeta signaling. *FEBS Letters*, **2006**, 580, 2811-20	3.8	598
141	Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. *Cell*, **2006**, 125, 929-41	56.2	299
140	Cancer metastasis: building a framework. *Cell*, **2006**, 127, 679-95	56.2	3126
139	Is cancer a disease of self-seeding?. *Nature Medicine*, **2006**, 12, 875-8	50.5	276
138	Identifying site-specific metastasis genes and functions. *Cold Spring Harbor Symposia on Quantitative Biology*, **2005**, 70, 149-58	3.9	79
137	Genes that mediate breast cancer metastasis to lung. *Nature*, **2005**, 436, 518-24	50.4	2242
136	TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. *Cancer Cell*, **2005**, 8, 369-80	24.3	815
135	Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells. *Journal of Biological Chemistry*, **2005**, 280, 32018-25	5.4	26
134	Smad transcription factors. *Genes and Development*, **2005**, 19, 2783-810	12.6	1789
133	Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13909-14	11.5	452
132	Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *Journal of Clinical Investigation*, **2005**, 115, 44-55	15.9	499
131	Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 15231-6	11.5	196
130	Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor-beta. *Journal of Biological Chemistry*, **2004**, 279, 23759-65	5.4	16
129	Nucleocytoplasmic shuttling of signal transducers. *Nature Reviews Molecular Cell Biology*, **2004**, 5, 209-19	18.7	217
128	G1 cell-cycle control and cancer. *Nature*, **2004**, 432, 298-306	50.4	929
127	Epithelial-mesenchymal transitions: twist in development and metastasis. *Cell*, **2004**, 118, 277-9	56.2	1198
126	Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. *Cell*, **2004**, 117, 211-23	56.2	796
125	Platelets and metastasis revisited: a novel fatty link. *Journal of Clinical Investigation*, **2004**, 114, 1691-1693	15.9	79

124	Platelets and metastasis revisited: a novel fatty link. *Journal of Clinical Investigation*, **2004**, 114, 1691-3	15.9	42
123	Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression. *Journal of Biological Chemistry*, **2003**, 278, 35444-50	5.4	74
122	Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. *Journal of Cell Biology*, **2003**, 162, 1089-98	7.3	265
121	Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA binding. *Journal of Biological Chemistry*, **2003**, 278, 20327-31	5.4	58
120	Integration of Smad and MAPK pathways: a link and a linker revisited. *Genes and Development*, **2003** , 17, 2993-7	12.6	176
119	A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell*, **2003**, 3, 537-49	24.3	2050
118	Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. *Nature Reviews Cancer*, **2003**, 3, 807-21	31.3	1333
117	Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell*, **2003**, 113, 685-700	56.2	4695
116	A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. *Molecular Cell*, **2003**, 11, 915-26	17.6	441
115	Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import. *Journal of Biological Chemistry*, **2003**, 278, 42569-77	5.4	94
114	Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8430-5	11.5	375
113	Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. *Nature*, **2002**, 419, 729-34	50.4	560
112	Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. *Blood*, **2002**, 99, 3179-87	2.2	267
111	Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. *Journal of Biological Chemistry*, **2002**, 277, 3176-85	5.4	239
110	E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. *Cell*, **2002**, 110, 19-32	56.2	401
109	Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus. *Molecular Cell*, **2002**, 10, 271-82	17.6	211
108	Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. *EMBO Journal*, **2001**, 20, 128-36	13	128
107	Repression of p15INK4b expression by Myc through association with Miz-1. *Nature Cell Biology*, **2001**, 3, 392-9	23.4	461

106	TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. *Nature Cell Biology*, **2001**, 3, 400-8	23.4	404
105	Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 992-9	11.5	276
104	The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. *Molecular Cell*, **2001**, 8, 671-82	17.6	310
103	Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. *Molecular Cell*, **2001**, 8, 1277-89	17.6	244
102	BF-1 interferes with transforming growth factor beta signaling by associating with Smad partners. *Molecular and Cellular Biology*, **2000**, 20, 6201-11	4.8	86
101	Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. *Nature Genetics*, **2000**, 25, 205-8	36.3	337
100	The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. *Nature Cell Biology*, **2000**, 2, 559-62	23.4	128
99	How cells read TGF-beta signals. *Nature Reviews Molecular Cell Biology*, **2000**, 1, 169-78	48.7	1589
98	Networks of tumor suppressors. Workshop: tumor suppressor networks. *EMBO Reports*, **2000**, 1, 115-9	6.5	4
97	Transcriptional control by the TGF-beta/Smad signaling system. *EMBO Journal*, **2000**, 19, 1745-54	13	1589
96	Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. *Journal of Biological Chemistry*, **2000**, 275, 27973-8	5.4	123
95	Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. *Journal of Biological Chemistry*, **2000**, 275, 40282-7	5.4	77
94	Different sensitivity of the transforming growth factor-beta cell cycle arrest pathway to c-Myc and MDM-2. *Journal of Biological Chemistry*, **2000**, 275, 32066-70	5.4	15
93	Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway. *Journal of Biological Chemistry*, **2000**, 275, 40710-7	5.4	93
92	TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell*, **2000**, 103, 295-309	56.2	2036
91	OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. *Cell*, **2000**, 100, 229-40	56.2	378
90	Structural basis of Smad2 recognition by the Smad anchor for receptor activation. *Science*, **2000**, 287, 92-7	33.3	251
89	BF-1 Interferes with Transforming Growth Factor β Signaling by Associating with Smad Partners. *Molecular and Cellular Biology*, **2000**, 20, 6201-6211	4.8	2

88	Controlling TGF-signaling. *Genes and Development*, **2000**, 14, 627-644	12.6	879
87	Controlling TGF-beta signaling. *Genes and Development*, **2000**, 14, 627-44	12.6	1231
86	Multiple modes of repression by the Smad transcriptional corepressor TGIF. *Journal of Biological Chemistry*, **1999**, 274, 37105-10	5.4	140
85	Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. *Journal of Biological Chemistry*, **1999**, 274, 3672-7	5.4	172
84	Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. *Journal of Biological Chemistry*, **1999**, 274, 33637-43	5.4	121
83	Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. *Nature*, **1999**, 397, 710-3	50.4	704
82	Ubiquitin-dependent degradation of TGF-beta-activated smad2. *Nature Cell Biology*, **1999**, 1, 472-8	23.4	299
81	Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. *Cell*, **1999**, 96, 425-36	56.2	375
80	A Smad transcriptional corepressor. *Cell*, **1999**, 97, 29-39	56.2	473
79	TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. *Journal of Clinical Investigation*, **1999**, 103, 197-206	15.9	774
78	Physical and functional interaction of SMADs and p300/CBP. *Journal of Biological Chemistry*, **1998**, 273, 22865-8	5.4	275
77	Carboxy-terminally truncated Gli3 proteins associate with Smads. *Nature Genetics*, **1998**, 20, 325-6	36.3	96
76	TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. *Trends in Molecular Medicine*, **1998**, 4, 257-62		135
75	SMADs: mediators and regulators of TGF-beta signaling. *Current Opinion in Genetics and Development*, **1998**, 8, 103-11	4.9	423
74	Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. *Cell*, **1998**, 94, 585-94	56.2	830
73	TGF-beta signal transduction. *Annual Review of Biochemistry*, **1998**, 67, 753-91	29.1	3919
72	Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. *Journal of the National Cancer Institute*, **1998**, 90, 1284-91	9.7	243
71	Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. *Journal of Biological Chemistry*, **1997**, 272, 25863-72	5.4	214

70	Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding. *Journal of Biological Chemistry*, **1997**, 272, 17160-5	5.4	92
69	Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. *Nature*, **1997**, 387, 417-22	50.4	328
68	Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. *Nature*, **1997** , 388, 82-7	50.4	310
67	A structural basis for mutational inactivation of the tumour suppressor Smad4. *Nature*, **1997**, 388, 87-93	50.4	382
66	Mechanism of TGFbeta receptor inhibition by FKBP12. *EMBO Journal*, **1997**, 16, 3866-76	13	285
65	TGFbeta signaling: receptors, transducers, and Mad proteins. *Cell*, **1996**, 85, 947-50	56.2	814
64	Nomenclature: vertebrate mediators of TGFbeta family signals. *Cell*, **1996**, 87, 173	56.2	150
63	A human Mad protein acting as a BMP-regulated transcriptional activator. *Nature*, **1996**, 381, 620-3	50.4	594
62	Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. *Nature*, **1996**, 382, 325-31	50.4	804
61	Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. *Nature*, **1996**, 383, 832-6	50.4	818
60	Interaction of transforming growth factor-beta receptor I with farnesyl-protein transferase-alpha in yeast and mammalian cells. *Journal of Biological Chemistry*, **1996**, 271, 13931-4	5.4	41
59	Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. *Journal of Biological Chemistry*, **1996**, 271, 11376-82	5.4	340
58	Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. *Nature*, **1995**, 375, 159-61	50.4	498
57	Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. *Nature*, **1995**, 376, 313-20	50.4	1227
56	Signaling activity of homologous and heterologous transforming growth factor-beta receptor kinase complexes. *Journal of Biological Chemistry*, **1995**, 270, 7134-41	5.4	66
55	Cell cycle 1995: constructing cell physiology with molecular building blocks. *Current Opinion in Cell Biology*, **1995**, 7, 769-72	9	11
54	Drosophila Dpp signaling is mediated by the punt gene product: a dual ligand-binding type II receptor of the TGF beta receptor family. *Cell*, **1995**, 80, 899-908	56.2	242
53	Mammalian antiproliferative signals and their targets. *Current Opinion in Genetics and Development*, **1995**, 5, 91-6	4.9	113

52	Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. *Molecular and Cellular Biology*, **1994**, 14, 5961-74	4.8	310
51	The TGF-beta family and its composite receptors. *Trends in Cell Biology*, **1994**, 4, 172-8	18.3	500
50	Mechanism of activation of the TGF-beta receptor. *Nature*, **1994**, 370, 341-7	50.4	2048
49	Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. *Nature*, **1994**, 372, 570-3	50.4	857
48	Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. *Cell*, **1994**, 79, 487-96	56.2	712
47	Identification of two bone morphogenetic protein type I receptors in Drosophila and evidence that Brk25D is a decapentaplegic receptor. *Cell*, **1994**, 78, 239-50	56.2	237
46	Characterization and relationship of Dpp receptors encoded by the saxophone and thick veins genes in Drosophila. *Cell*, **1994**, 78, 251-61	56.2	278
45	Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell*, **1994**, 78, 59-66	56.2	1928
44	TGF-beta receptors and actions. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1994**, 1222, 71-80	4.9	245
43	Dexamethasone enhancement of betaglycan (TGF-beta type III receptor) gene expression in osteoblast-like cells. *Experimental Cell Research*, **1994**, 211, 301-6	4.2	30
42	Transforming growth factor receptor gene TGFBR2 maps to human chromosome band 3p22. *Genomics*, **1994**, 20, 114-5	4.3	44
41	Betaglycan presents ligand to the TGF beta signaling receptor. *Cell*, **1993**, 73, 1435-44	56.2	787
40	Membrane-anchored growth factors. *Annual Review of Biochemistry*, **1993**, 62, 515-41	29.1	593
39	Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. *European Journal of Immunology*, **1993**, 23, 2340-5	6.1	180
38	The daf-4 gene encodes a bone morphogenetic protein receptor controlling C. elegans dauer larva development. *Nature*, **1993**, 365, 644-9	50.4	327
37	Negative regulators of growth. *Current Opinion in Genetics and Development*, **1992**, 2, 28-32	4.9	17
36	Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. *Cell*, **1992**, 68, 97-108	56.2	455
35	TGF beta signals through a heteromeric protein kinase receptor complex. *Cell*, **1992**, 71, 1003-14	56.2	1368

34	Receptors for the TGF-beta family. *Cell*, **1992**, 69, 1067-70	56.2	664
33	The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGF alpha into soluble growth factor. *Cell*, **1992**, 71, 1157-65	56.2	131
32	TGF-beta receptors. *Molecular Reproduction and Development*, **1992**, 32, 99-104	2.6	92
31	Transforming growth factor-alpha. *Biochemical Society Transactions*, **1991**, 19, 259-62	5.1	11
30	A helping hand from proteoglycans. *Current Biology*, **1991**, 1, 117-9	6.3	19
29	Role of transforming growth factor-beta in chondrogenic pattern formation in the embryonic limb: stimulation of mesenchymal condensation and fibronectin gene expression by exogenenous TGF-beta and evidence for endogenous TGF-beta-like activity. *Developmental Biology*, **1991**, 145, 99-109	3.1	208
28	Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. *Cell*, **1991**, 67, 785-95	56.2	601
27	Mechanisms in TGF-beta action. *Novartis Foundation Symposium*, **1991**, 157, 51-9; discussion 59-65		10
26	TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties. *Annals of the New York Academy of Sciences*, **1990**, 593, 59-72	6.5	207
25	Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. *Cell*, **1990**, 62, 175-85	56.2	731
24	The transforming growth factor-beta family. *Annual Review of Cell Biology*, **1990**, 6, 597-641		2825
23	The TGF-alpha precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. *Cell*, **1989**, 56, 495-506	56.2	438
22	Characterization of high molecular weight transforming growth factor alpha produced by rat hepatocellular carcinoma cells. *Biochemistry*, **1988**, 27, 6487-94	3.2	98
21	Identification of receptors for type-beta transforming growth factor. *Methods in Enzymology*, **1987**, 146, 174-95	1.7	120
20	Purification of type-alpha transforming growth factor from transformed cells. *Methods in Enzymology*, **1987**, 146, 103-12	1.7	3
19	Identification of receptor proteins for type-alpha transforming growth factor. *Methods in Enzymology*, **1987**, 146, 143-53	1.7	6
18	The TGF-beta family of growth and differentiation factors. *Cell*, **1987**, 49, 437-8	56.2	697
17	The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. *Cell*, **1987**, 48, 409-15	56.2	668

16	Multiple type-beta transforming growth factors and their receptors. *Journal of Cellular Physiology*, **1987**, Suppl 5, 43-7	7	51
15	Integral membrane glycoprotein properties of the prohormone pro-transforming growth factor-alpha. *Nature*, **1987**, 326, 883-5	50.4	95
14	Two forms of transforming growth factor-beta distinguished by multipotential haematopoietic progenitor cells. *Nature*, **1987**, 329, 539-41	50.4	358
13	Internalization of transforming growth factor-beta and its receptor in BALB/c 3T3 fibroblasts. *Journal of Cellular Physiology*, **1986**, 128, 216-22	7	73
12	Human platelet-derived transforming growth factor-beta stimulates parameters of bone growth in fetal rat calvariae. *Endocrinology*, **1986**, 119, 2306-12	4.8	162
11	[14] Affinity cross-linking of receptors for insulin and the insulin-like growth factors I and II. *Methods in Enzymology*, **1985**, 109, 179-187	1.7	10
10	Modulation of type alpha transforming growth factor receptors by a phorbol ester tumor promoter. *Journal of Cellular Biochemistry*, **1985**, 27, 23-30	4.7	8
9	The transforming growth factors. *Trends in Biochemical Sciences*, **1985**, 10, 237-240	10.3	55
8	The insulin receptor: structural features. *Trends in Biochemical Sciences*, **1981**, 6, 222-225	10.3	67
7	Structural features of the insulin effector system: relation to hexose transport activation. *Annals of the New York Academy of Sciences*, **1980**, 358, 282-91	6.5	3
6	Multiple phosphorylation of rabbit muscle glycogen synthase by glycogen synthase kinase-1. Relationship between phosphorylation state and kinetic properties. *FEBS Letters*, **1979**, 106, 279-83	3.8	11
5	Glycogen synthase: a new activity ratio assay expressing a high sensitivity to the phosphorylation state. *FEBS Letters*, **1979**, 106, 284-8	3.8	157
4	The inactivation of glycogen phosphorylase is not a prerequisite for the activation of liver glycogen synthase. *FEBS Letters*, **1979**, 99, 321-4	3.8	34
3	Insulin control of rat hepatocyte glycogen synthase and phosphorylase in the absence of glucose. *FEBS Letters*, **1977**, 82, 317-20	3.8	57
2	Anti-tumor effects of an Id antagonist with no acquired resistance		3
1	Cytotoxic lymphocytes use mechanosurveillance to target biophysical vulnerabilities in cancer		2